View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
October 30, 2012

AstraZeneca begins Phase III FALCON study of fulvestrant

AstraZeneca has announced the commencement of its FALCON Phase III study evaluating fulvestrant in patients with hormone receptor-positive advanced breast cancer.

AstraZeneca has announced the commencement of its FALCON Phase III study evaluating fulvestrant in patients with hormone receptor-positive advanced breast cancer.

The study will determine the safety and tolerability profile of fulvestrant 500mg compared to anastrozole 1mg in 450 postmenopausal patients who were not previously treated with any hormonal therapy.

University of Nottingham Royal Derby Hospital, Graduate Entry Medicine and Health School professor of medicine Dr John Robertson said; "The FALCON study is the first Phase III study designed to investigate the potential role of the 500 mg dose of fulvestrant in the treatment of hormone receptor positive advanced breast cancer in patients who have not been previously treated with any hormonal therapy."

"The study will determine the safety and tolerability profile of fulvestrant 500mg compared to anastrozole 1mg in 450 postmenopausal patients who were not previously treated with any hormonal therapy."

FALCON study is believed to show an impact on clinical practice relating to endocrine treatment options for women with hormone receptor-positive, locally advanced or metastatic breast cancer.

Safety and efficacy results from the Phase II FIRST study have formed the basis for FALCON’s design.

The double-blind, parallel group, multicentre study will randomise subjects in 1:1 with either fulvestrant on days 0, 14 (±3), 28 (±3), and every 28 (±3) days afterwards, plus a placebo to match the anastrozole administration plan, or anastrozole plus a placebo to go with the fulvestrant administration.

AstraZeneca medical science director Dr Yuri Rukazenkov said; "The FALCON trial is part of AstraZeneca’s commitment to the continued study and evaluation of treatment options for metastatic breast cancer, and developing and optimising breast cancer therapies for all patient groups."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena